Input the time since completion of anti-H. pylori therapy and PPI cessation to visualize the testing eligibility profile.
Guidelines & Evidence
Clinical Details
Section 1
When to Use
Treatment Principles
Mandatory treatment for all H. pylori-positive symptomatic patients
Selecting empirical therapy based on local antibiotic resistance patterns (especially Clarithromycin)
Standardizing therapy durations to 14 days to maximize cure rates
Maastricht VI / Florence Consensus
The 2022 update emphasizes Bismuth-based Quadruple Therapy as the preferred first-line option in high-resistance areas (>15% Clarithromycin resistance), which now includes most of North America and Europe.
Triple Therapy: PPI (BID) + Amoxicillin (BID) + Clarithromycin (BID). (ONLY if local resistance is known to be < 15%).
Rescue (Salvage) Therapies
01
Levofloxacin Triple: PPI (BID) + Amoxicillin (BID) + Levofloxacin (QD/BID). Ensure no prior fluorquinolone allergy.
02
Rifabutin Triple: PPI (BID) + Amoxicillin (BID) + Rifabutin (QD). Reserved for multi-drug resistance.
Section 3
Pearls/Pitfalls
Why Bismuth is Back
Metronidazole and Clarithromycin resistance have significantly eroded the efficacy of "Simple Triple Therapy." Bismuth has three advantages: it has a direct antimicrobial effect, it breaks down the H. pylori biofilm, and there is virtually no known H. pylori resistance to it.
Penicillin Allergy
In Penicillin-allergic patients, the Bismuth Quadruple regimen is the mandatory first-line choice. Avoid Clarithromycin-Metronidazole triple therapy due to extremely high failure rates.
Clinical Pearls
Use high-dose PPI (e.g., Esomeprazole 40mg BID) to maximize gastric pH, which increases the efficacy of antibiotics
Probiotics (especially B. infantis or S. boulardii) may reduce GI side effects and improve compliance, but do not directly increase cure rates
Alcohol must be avoided with Metronidazole-containing regimens due to the disulfiram-like reaction
Section 4
Next Steps
Confirming Eradication
01
Wait ≥ 4 weeks after the end of antibiotics.
02
Ensure the patient is off PPIs for at least 2 weeks.
03
Perform Urea Breath Test (UBT) or fecal Stool Antigen.
Complementary Tools
H. pylori Diagnostic Algorithm
Correa Cascade (Gastritis Staging)
Peptic Ulcer Re-bleed Risk
Section 5
Evidence Appraisal
Maastricht VI Consensus (2022)
Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report.
Malfertheiner P et al. • Gut. 2022;71(9):1724-1762. The definitive authority for modern clinicians.
Since 1996, the European Helicobacter and Microbiota Study Group has met in Maastricht to standardize the global response to H. pylori. The guidelines have evolved from simple acid suppression to the multi-drug quadruple regimens required to combat 21st-century antibiotic resistance.
